Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrew Seidman

Showing results (21-30 of 26) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 26 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 30, 2008
Racial differences in clinical outcomes from metastatic breast cancer: a pooled analysis of CALGB 9342 and 9840--Cancer and Leukemia Group BBlase N Polite, Constance Cirrincione, Gini F Fleming, et al.
Journal of Neuro-Oncology|June 8, 2020
Cerebrospinal fluid circulating tumor cells as a quantifiable measurement of leptomeningeal metastases in patients with HER2 positive cancerRachna Malani, Martin Fleisher, Priya Kumthekar, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 8, 2008
The safety of dose-dense doxorubicin and cyclophosphamide followed by paclitaxel with trastuzumab in HER-2/neu overexpressed/amplified breast cancerChau Dang, Monica Fornier, Steven Sugarman, et al.
Breast Cancer Research and Treatment|April 25, 2019
Examination and prognostic implications of the unique microenvironment of breast cancer brain metastasesMaria J Sambade, Grace Prince, Allison M Deal, et al.
Lancet (London, England)|December 17, 2023
Standard-of-care systemic therapy with or without stereotactic body radiotherapy in patients with oligoprogressive breast cancer or non-small-cell lung cancer (Consolidative Use of Radiotherapy to Block [CURB] oligoprogression): an open-label, randomised, controlled, phase 2 studyChiaojung Jillian Tsai, Jonathan T Yang, Narek Shaverdian, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 26, 2011
A feasibility study of bevacizumab plus dose-dense doxorubicin-cyclophosphamide (AC) followed by nanoparticle albumin-bound paclitaxel in early-stage breast cancerHeather L McArthur, Hope Rugo, Benjamin Nulsen, et al.
Pageof 3

Showing results (21-30 of 26) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 26 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 30, 2008
Racial differences in clinical outcomes from metastatic breast cancer: a pooled analysis of CALGB 9342 and 9840--Cancer and Leukemia Group BBlase N Polite, Constance Cirrincione, Gini F Fleming, et al.
Journal of Neuro-Oncology|June 8, 2020
Cerebrospinal fluid circulating tumor cells as a quantifiable measurement of leptomeningeal metastases in patients with HER2 positive cancerRachna Malani, Martin Fleisher, Priya Kumthekar, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 8, 2008
The safety of dose-dense doxorubicin and cyclophosphamide followed by paclitaxel with trastuzumab in HER-2/neu overexpressed/amplified breast cancerChau Dang, Monica Fornier, Steven Sugarman, et al.
Breast Cancer Research and Treatment|April 25, 2019
Examination and prognostic implications of the unique microenvironment of breast cancer brain metastasesMaria J Sambade, Grace Prince, Allison M Deal, et al.
Lancet (London, England)|December 17, 2023
Standard-of-care systemic therapy with or without stereotactic body radiotherapy in patients with oligoprogressive breast cancer or non-small-cell lung cancer (Consolidative Use of Radiotherapy to Block [CURB] oligoprogression): an open-label, randomised, controlled, phase 2 studyChiaojung Jillian Tsai, Jonathan T Yang, Narek Shaverdian, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 26, 2011
A feasibility study of bevacizumab plus dose-dense doxorubicin-cyclophosphamide (AC) followed by nanoparticle albumin-bound paclitaxel in early-stage breast cancerHeather L McArthur, Hope Rugo, Benjamin Nulsen, et al.
Pageof 3